Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: Results from a randomized controlled trial

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 165-171

  Teoh, A Y B ^a   Chiu, P W Y ^a   Yeung, W K ^b   Liu, S Y W ^a   Wong, S K H ^a   Ng, E K W ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Carcinoma of esophagus; Chemoradiation; Chemoradiotherapy; Esophagectomy; Squamous cell esophageal carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL;

AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FOLLOW UP; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REHYDRATION;

EID: 84871567749     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds206     Document Type: Article

References (29)

1. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010; 17: 1721-1724.
2. Siewert JR, Stein HJ, Feith M et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001; 234: 360-369.
3. Kranzfelder M, Schuster T, Geinitz H et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 2011; 98: 768-783.
4. Gebski V, Burmeister B, Smithers BM et al. Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234.
5. Sjoquist KM, Burmeister BH, Smithers BM et al. Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692.
6. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317.
7. Bedenne L, Michel P, Bouché O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-1168.
8. Chiu PW, Chan AC, Leung SF et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005; 9: 794-802.
9. Teoh AY, Chiu PW, Wong TC et al. Functional performance and quality of life in patients with squamous esophageal carcinoma receiving surgery or chemoradiation: results from a randomized trial. Ann Surg 2011; 253: 1-5.
10. Meluch AA, Greco FA, Gray JR et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 2003; 9: 251-260.
11. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686.
12. Darnton SJ, Archer VR, Stocken DD et al. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol 2003; 21: 4009-4015.
13. Meredith KL, Weber JM, Turaga KK et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol 2010; 17: 1159-1167.
14. Loh M, Koh KX, Yeo BH et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer 2009; 45(14): 2562-2568.
15. Lee W, Nelson R, Akmal Y et al. Racial and ethnic disparities in outcomes with radiation therapy for rectal adenocarcinoma. Int J Colorectal Dis 2012; 27(6): 737-749.
16. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366(9496): 1527-1537.
17. Shibata T, Kokubu A, Saito S et al. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 2011; 13(9): 864-873.
18. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174.
19. Hagen JA, DeMeester SR, Peters JH et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 2001; 234: 520-530.
20. Law S, Wong J. Two-field dissection is enough for esophageal cancer. Dis Esophagus 2001; 14: 98-103.
21. Isono K, Sato H, Nakayama K. Results of a nationwide study on the three fields of lymph node dissection in esophageal cancer. Oncology 1991; 51: 931-935.
22. Lerut T, Nafteux P, Moons J et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240: 962-972.
23. Nguyen NT, Hinojosa MW, Smith BR et al. Minimally invasive esophagectomy: lessons learned from 104 operations. Ann Surg 2008; 248: 1081-1091.
24. Swisher SG, Maish M, Erasmus JJ et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004; 78: 1152-1160.
25. Vallböhmer D, Hölscher AH, Dietlein M et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009; 250: 888-8894.
26. Levine EA, Farmer MR, Clark P et al. Predictive value of 18-fluoro-deoxyglucose- positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006; 243: 472-478.
27. Jost C, Binek J, Schuller JC et al. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02). Gastrointest Endosc 2010; 71: 1114-1121.
28. Chang WL, Lin FC, Yen CJ et al. Tumor length assessed by miniprobe endosonography can predict the survival of the advanced esophageal squamous cell carcinoma with stricture receiving concurrent chemoradiation. Dis Esophagus 2011; 24: 590-595.
29. Schneider PM, Metzger R, Schaefer H et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 2008; 248: 902-908.